NEW YORK--(BUSINESS WIRE)--ChipDX LLC, a New York-based online molecular diagnostics and personalized medicine company, discovered and validated a genetic signature for early-stage colon cancer and is developing an online screening application to enable clinicians to more accurately identify risk of recurrence. In the study, published in the December issue of the British Journal of Cancer, ChipDX demonstrates how the 163-gene signature stratifies colon cancer patients into high- and low-risk groups for recurrence with greater accuracy than current methods.
